Viet Nam Pharmaceutical - JSC (HSTC:DVN) Piotroski F-Score: 4 (As of Jul. 09, 2026) — 33% Below Median


HSTC:DVN Viet Nam Pharmaceutical Corp - JSC HSTC:DVN
79 GF Score
Price ₫20,000.00
GF Value ₫22,074.26
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Viet Nam Pharmaceutical - JSC Piotroski F-Score?

Viet Nam Pharmaceutical - JSC HSTC:DVN 79 Piotroski F-Score is 4 as of Jul. 09, 2026, which is 33% below its 10-year median of 6.00. GuruFocus rates HSTC:DVN with a GF Score™ of 79/100 and a GF Value™ of ₫22,074.26 (Fairly Valued). The stock has 5 warning signs investors should review. Among 980 Drug Manufacturers companies, Viet Nam Pharmaceutical - JSC ranks worse than 61.02% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Viet Nam Pharmaceutical - JSC has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Viet Nam Pharmaceutical - JSC's Piotroski F-Score or its related term are showing as below:

HSTC:DVN' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 6   Max: 8
Current: 4

During the past 7 years, the highest Piotroski F-Score of Viet Nam Pharmaceutical - JSC was 8. The lowest was 4. And the median was 6.

Viet Nam Pharmaceutical - JSC  (HSTC:DVN) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Viet Nam Pharmaceutical - JSC Piotroski F-Score Related Terms


Viet Nam Pharmaceutical - JSC Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Viet Nam Pharmaceutical - JSC's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viet Nam Pharmaceutical - JSC Piotroski F-Score Chart

Viet Nam Pharmaceutical - JSC Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial 5.00 7.00 6.00 6.00 4.00

Viet Nam Pharmaceutical - JSC Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 4.00 5.00 4.00 4.00

HSTC:DVN vs ZTS, UTHR: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Viet Nam Pharmaceutical - JSC's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viet Nam Pharmaceutical - JSC Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Viet Nam Pharmaceutical - JSC's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Viet Nam Pharmaceutical - JSC's Piotroski F-Score falls into.


HSTC:DVN
79GF Score
Viet Nam Pharmaceutical Corp - JSC HSTC:DVN
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 140779.678 + 72563.401 + 331545.814 + 142035.348 = ₫686,924 Mil.
Cash Flow from Operations was -65241.029 + -41404.781 + -87280.734 + -140714.712 = ₫-334,641 Mil.
Revenue was 1398809.566 + 1326945.959 + 1691262.309 + 1237438.359 = ₫5,654,456 Mil.
Gross Profit was 135477.687 + 125887.182 + 146563.154 + 137914.556 = ₫545,843 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(6629281.266 + 6924744.755 + 6802007.724 + 7652469.962 + 7750853.302) / 5 = ₫7151871.4018 Mil.
Total Assets at the begining of this year (Mar25) was ₫6,629,281 Mil.
Long-Term Debt & Capital Lease Obligation was ₫29,797 Mil.
Total Current Assets was ₫4,732,361 Mil.
Total Current Liabilities was ₫3,538,119 Mil.
Net Income was 249011.545 + 60031.346 + 44126.803 + 72631.042 = ₫425,801 Mil.

Revenue was 1533842.371 + 1219685.421 + 1578070.547 + 1242917.502 = ₫5,574,516 Mil.
Gross Profit was 156190.103 + 129100.361 + 176208.715 + 138463.146 = ₫599,962 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(5993917.959 + 6306267.99 + 6162095.581 + 6455457.886 + 6629281.266) / 5 = ₫6309404.1364 Mil.
Total Assets at the begining of last year (Mar24) was ₫5,993,918 Mil.
Long-Term Debt & Capital Lease Obligation was ₫30,196 Mil.
Total Current Assets was ₫4,612,672 Mil.
Total Current Liabilities was ₫3,005,082 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Viet Nam Pharmaceutical - JSC's current Net Income (TTM) was 686,924. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Viet Nam Pharmaceutical - JSC's current Cash Flow from Operations (TTM) was -334,641. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=686924.241/6629281.266
=0.10361972

ROA (Last Year)=Net Income/Total Assets (Mar24)
=425800.736/5993917.959
=0.0710388

Viet Nam Pharmaceutical - JSC's return on assets of this year was 0.10361972. Viet Nam Pharmaceutical - JSC's return on assets of last year was 0.0710388. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Viet Nam Pharmaceutical - JSC's current Net Income (TTM) was 686,924. Viet Nam Pharmaceutical - JSC's current Cash Flow from Operations (TTM) was -334,641. ==> -334,641 <= 686,924 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=29797.177/7151871.4018
=0.00416635

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=30195.766/6309404.1364
=0.00478583

Viet Nam Pharmaceutical - JSC's gearing of this year was 0.00416635. Viet Nam Pharmaceutical - JSC's gearing of last year was 0.00478583. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=4732360.672/3538118.571
=1.33753592

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=4612672.239/3005082.309
=1.53495704

Viet Nam Pharmaceutical - JSC's current ratio of this year was 1.33753592. Viet Nam Pharmaceutical - JSC's current ratio of last year was 1.53495704. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Viet Nam Pharmaceutical - JSC's number of shares in issue this year was 237. Viet Nam Pharmaceutical - JSC's number of shares in issue last year was 237. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=545842.579/5654456.193
=0.09653317

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=599962.325/5574515.841
=0.10762591

Viet Nam Pharmaceutical - JSC's gross margin of this year was 0.09653317. Viet Nam Pharmaceutical - JSC's gross margin of last year was 0.10762591. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=5654456.193/6629281.266
=0.85295162

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=5574515.841/5993917.959
=0.93002872

Viet Nam Pharmaceutical - JSC's asset turnover of this year was 0.85295162. Viet Nam Pharmaceutical - JSC's asset turnover of last year was 0.93002872. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+0+1+0+1+0+1+0+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Viet Nam Pharmaceutical - JSC has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
Viet Nam Pharmaceutical - JSC (HSTC:DVN) has a Piotroski F-Score of 4 as of Jul. 09, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Viet Nam Pharmaceutical - JSC and its competitors. This is 33% below median its historical median of 6.00. Over the past decade, Viet Nam Pharmaceutical - JSC's Piotroski F-Score has ranged from 4.00 to 8.00. According to the industry distribution chart, Viet Nam Pharmaceutical - JSC ranks #598 out of 980 companies in the Drug Manufacturers industry, placing it in the top 61%.
Is Viet Nam Pharmaceutical - JSC's Piotroski F-Score too high?
Viet Nam Pharmaceutical - JSC's current Piotroski F-Score of 4 is 33% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 8.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Viet Nam Pharmaceutical - JSC's value of 4 is 20% below this industry median. Based on the distribution chart, Viet Nam Pharmaceutical - JSC ranks #598 out of 980 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Viet Nam Pharmaceutical - JSC has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Viet Nam Pharmaceutical - JSC's Piotroski F-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Viet Nam Pharmaceutical - JSC ranks #598 out of 980 companies for Piotroski F-Score. This places Viet Nam Pharmaceutical - JSC in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Viet Nam Pharmaceutical - JSC's value of 4 is 20% below this benchmark. Historically, Viet Nam Pharmaceutical - JSC's own Piotroski F-Score has ranged from 4.00 to 8.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Viet Nam Pharmaceutical - JSC has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 980 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viet Nam Pharmaceutical - JSC's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Viet Nam Pharmaceutical - JSC and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viet Nam Pharmaceutical - JSC's current Piotroski F-Score is 4, which is 33% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viet Nam Pharmaceutical - JSC stock overvalued right now?
Based on GuruFocus' analysis, Viet Nam Pharmaceutical - JSC (HSTC:DVN) is currently considered Fairly Valued. The stock's GF Value™ is ₫22,074.26, compared to a current price of ₫20,000.00 — trading 9.4% below its estimated fair value. The current Piotroski F-Score is 4, which is 33% below median its 10-year median of 6.00 and 20% below the Drug Manufacturers industry median of 5.00. Viet Nam Pharmaceutical - JSC's overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Viet Nam Pharmaceutical - JSC (HSTC:DVN), the current Piotroski F-Score is 4 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Viet Nam Pharmaceutical - JSC (HSTC:DVN) Overvalued in 2026?

Based on GuruFocus' analysis, Viet Nam Pharmaceutical - JSC stock appears to be undervalued. The current stock price of ₫20,000.00 is trading 9.4% below its estimated GF Value™ of ₫22,074.26. GuruFocus considers Viet Nam Pharmaceutical - JSC to be Fairly Valued.

Key valuation signals for HSTC:DVN:

  • Piotroski F-Score: 4 (33% below median its 10-year median of 6.00)
  • GF Value™: ₫22,074.26 vs. price of ₫20,000.00 (9.4% below fair value)
  • GF Score™: 79/100 with 5 warning signs
  • Industry Position: 20% below the Drug Manufacturers median (#598 of 980)

No single metric tells the full story. See the HSTC:DVN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Viet Nam Pharmaceutical - JSC Business Description

Address 12 Ngo Tat To, Van Mieu Ward, Dong Da District, Hanoi, VNM
Viet Nam Pharmaceutical Corp - JSC is engaged in the manufacturing of drugs. The company provides testing services for drugs and medicinal ingredients.
79GF Score

Get the complete analysis for HSTC:DVN

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₫20,000.00
Price
₫22,074.26
GF Value